Sirio Pharma Co. Ltd (SIRIO) – the global nutraceutical contract development and manufacturing organization (CDMO) announces the opening of a gummy production plant at its new development and manufacturing facility in Ma’anshan (300km West of Shanghai, China).
This announcement comes 11 years after SIRIO opened its first gummy facility. The new site will be built in several phases and form a ‘Centre of Excellence’ covering an enormous 240,000sqm.
Phase Ⅰ of the site’s construction has just been completed and features a 26,000sqm gummy production plant and its associated building – designed to expedite development and manufacturing of gummy formulations for global customers.
“In the United States and Europe in particular, there is a significant growth potential in gummy formulations – as they are seen as a more consumer friendly dosage form. For many of the branded firms looking to enter this market early with customized formulations, we offer clear advantages. We can expedite development and even offer taste testing options during formulation. Alternatively, we also offer ready-to-go formulations for companies that are looking to enter the market quickly – because we have one of the largest ranges of existing gummy formulations of any global business. But as consumers become more discerning, we anticipate branded companies will increasingly need specialist gummy development partners and capabilities.” Rui Yang, CSO of SIRIO Pharma said.
The gummy production plant features integrated R&D and will increse production capacity to 2.4 billion gummies per year. SIRIO also expanded its ability to make innovative products such as liquid filled, centre-filled, swirled and multi-coloured gummies. In addition, SIRIO has hundreds of standard gummy formulation options suitable for market launch in the US and EU, and vegetarian options including carrageen and pectin, as well as sugar free and low-sugar options.
“The advantage of running an integrated site is that we can develop a much more tailored product for customers, while also expediting development timelines, thanks to a large team of in-house gummy specialists - more than 10 scientists and formulation engineers dedicated to gummies. We anticipate exponential growth for the gummy lines in 2019. And obviously, with the new capacity we have, we can supply even for the largest of nutraceutical brands” Rui Yang, CSO of SIRIO Pharma said.
Loren Israelsen, President, United Natural Products Alliance, on his recent visit to the new facility commented: “I have toured scores of dietary supplement factories around the world, but few equal Sirio's new gummy facility in terms of technology, state-of-the-art design and engineering, robotics, and R&D capabilities. This facility boasts world-class R&D and manufacturing and will help customers innovate new formulations for the fast-growing gummy market."
The company is predicting its market share for contract services in the United States and Europe will increase rapidly as a result.
Founded in 1993, Sirio Pharma Co., Ltd (SIRIO) is the leading global nutraceutical CDMO specialized in developing and manufacturing quality products including softgel, capsule, tablet, powder, gummy, oral liquid, probiotics and other dosage forms. The company has extensive capabilities with multiple manufacturing sites in China, as well as manufacturing facilities in Europe and marketing teams in the USA. SIRIO is devoted to offering one-stop solutions including product developing, manufacturing, packaging and logistics to its customers.
SIRIO is approved by TGA-GMP, NPA/UL GMP, BRC, UL's Management System 21 CFR Part 111, ISO 9001:2015 certification, and etc. Cooperating with many well-known nutraceutical companies, SIRIO is committed to providing products and service to customers all around the world.